Capricor Therapeutics, Inc.

CAPR Healthcare Biotechnology

Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023. In the quarter to June 2026, revenue fell 7.92%, EPS fell 22.8% and free cash flow fell 72.9%, each against the same quarter a year earlier.

6.88 0.59 −7.90%
Market cap
$434.3M
P/E
0.0×
Fwd P/E
−13.2×
Dividend yield
—
F-score
4/9
Altman Z
10.32
Beneish M
−2.61
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
— 4 3 4 3 3 3 1 4 2
P/E ratio
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 52.33 0.00
P/S ratio
— 21.82 5.45 34.30 223.49 172.12 4.73 7.21 13.66 11.83
Altman Z-Score
— 10.32 (2.15) (3.79) (0.31) 1.20 (9.87) (12.89) (1.49) (4.66)
Altman Z″-Score (non-manufacturers)
— 6.08 (8.76) (10.05) (3.49) (0.52) (19.12) (28.50) (7.64) (11.03)
P/FCF ratio
— 9.30 0.00 60.72 0.00 0.00 0.25 1.37 0.00 0.00
Beneish M-Score
— (2.61) 6.51 0.79 — — (3.62) (3.46) 3.38 (3.85)
P/Operating CF
— (32.85) (11.83) (13.70) (12.02) (13.90) (2.66) (3.20) (13.65) (13.60)
P/B ratio
— 3.34 6.07 8.02 2.16 1.89 0.69 2.61 3.24 0.00
Price to Tangible BV
— 3.34 6.07 8.02 2.16 1.89 0.70 2.64 3.27 0.00
EV/Sales
— 15.66 4.44 24.42 155.13 112.70 12.33 19.49 18.60 10.92
EV/EBITDA
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
— (8.72) (4.37) 13.69 (2.79) (3.48) (1.82) (2.35) (3.49) (3.02)
EV/FCF
— 6.67 (4.04) 43.23 (2.61) (4.60) 0.65 3.69 (3.48) (2.98)
Quick Ratio
8.88 7.70 1.59 1.78 8.53 10.99 11.11 6.17 9.10 3.63
Current Ratio
9.01 7.77 1.63 1.82 8.82 11.33 11.74 6.75 9.40 3.70
Net Debt/EBITDA
2.99 3.68 1.72 1.42 1.69 2.41 0.86 0.27 0.90 0.22
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.21% 30.38% 36.51% 20.75% 74.18%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.49 0.73 0.30 (3.47)
Asset Turnover
0.00 0.19 0.46 0.06 0.01 0.01 0.10 0.13 0.15 0.23
Operating CF/Net income
0.66 0.99 1.15 (0.17) 0.84 0.74 0.89 0.91 (5.85) 0.77
Capex/Depreciation
131.75 64.73 (1.92) (6.30) (4.87) (3.81) 17.44 143.84 (0.22) (1.54)
Interest Coverage
(35.51) — — (56.95) (364.15) — — (112.70) (32.25) (49.25)
ROE
(46.56%) (48.16%) (129.63%) (134.49%) (67.23%) (77.95%) (133.42%) (191.78%) 67.32% 747.04%
ROA
(39.91%) (35.31%) (40.96%) (63.48%) (52.73%) (59.73%) (75.06%) (119.05%) 13.89% (108.03%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% (1,463.42%) (2,130.18%) 0.00% 0.00%
Return on Tangible Assets
(34.39%) (27.36%) (88.63%) (121.47%) (58.72%) (43.28%) (75.74%) (195.00%) 16.87% (137.79%)
Average Days of Receivables
0.00 169.93 150.36 78.34 583.94 0.00 31.96 44.75 47.17 20.38
Research and Development Expense of Revenue
0.00% 224.37% 144.76% 855.07% 5,541.45% 2,725.43% 511.62% 721.96% 403.78% 401.19%
Selling, General and Administrative Expense of Revenue
0.00% 66.75% 50.87% 408.85% 3,108.33% 1,786.40% 357.92% 295.06% 178.62% 123.37%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01
Share Based Compensation of Revenue
0.00% 43.85% 29.36% 174.74% 1,210.98% 629.29% 69.75% 103.24% 64.16% 49.08%
Graham Net Nets
— 0.28 0.11 0.05 0.39 0.51 1.32 0.32 0.29 (0.10)
Graham Number
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5.72 22.25
Earnings Yield
— (8.70%) (16.99%) (30.65%) (29.69%) (27.41%) (168.75%) (129.27%) 1.91% (40.00%)
Free Cash Flow Yield
— 10.75% (20.16%) 1.65% (26.62%) (14.23%) 401.01% 73.15% (39.17%) (30.97%)
Revenue per Share
0.00 0.63 0.94 0.10 0.01 0.02 0.27 0.57 1.15 2.16
Operating CF per Share
(1.50) (1.14) (0.96) 0.20 (0.73) (0.65) (1.84) (4.71) (6.14) (7.79)
Capex per Share
5.35 2.62 (0.08) (0.14) (0.05) (0.04) 0.81 7.71 (0.01) (0.10)
Free Cash Flow per Share
3.85 1.48 (1.03) 0.06 (0.78) (0.68) (1.03) 3.00 (6.15) (7.90)
Cash per Share
6.84 4.30 1.47 1.69 1.51 2.10 2.66 2.56 6.41 9.46
Shareholders Equity per Share
6.58 4.13 0.84 0.48 1.36 1.81 1.84 1.57 4.84 (2.16)
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
6.58 4.13 0.84 0.48 1.36 1.81 1.84 1.57 4.84 (2.16)
Free Cash Flow
179.06 52.26 (27.64) 1.56 (18.01) (10.60) (3.82) 8.82 (14.26) (14.65)
Working Capital
287.10 142.36 19.59 19.30 32.30 30.71 9.65 7.22 14.04 13.21
Capital Expenditures
248.87 92.26 (2.05) (3.36) (1.20) (0.55) 3.00 22.68 (0.03) (0.19)
Net Current Asset Value
272.78 138.37 14.72 4.58 26.47 27.26 6.27 3.84 10.67 (4.64)
EV/EBIT
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.00 (4.14) 0.08 1.32 4.88 1.76 (2.99) (13.57) 0.01 0.05
Price to Operating Income
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.10 0.26 0.19 0.12 0.14 0.17 0.39 0.27 0.39 0.29
Cash ROIC
28.70% 17.60% (44.52%) 2.93% (27.18%) (17.40%) (19.01%) 56.79% (48.40%) (53.37%)
Accounts Receivable Turnover
0.00 2.15 4.61 5.43 1.02 0.00 6.86 6.08 9.39 18.38
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — — 0.00 0.00 — — — — —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — — 0.00 0.00 — — — — —
Average Receivables
5.21 10.37 5.46 0.47 0.24 — 0.15 0.27 0.28 0.22
Average Payables
2.47 4.77 5.59 4.32 3.22 1.81 1.08 1.46 2.60 3.21
Average Assets
263.22 114.61 54.41 45.71 37.97 22.87 10.18 12.76 17.51 17.41
Average Common Equity
225.63 84.03 17.19 21.58 29.78 17.52 5.73 7.92 3.61 (2.52)

Fold the line items

Columns are period end dates